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Clinical decision-making in remote rheumatology
consultations: a service evaluation of new patient
and inflammatory rheumatic disease follow-up
appointments
DEAR EDITOR, Owing to coronavirus disease 2019
(COVID-19), remote appointments have largely replaced
face-to-face consultations [1]. Although important to
reducing viral spread, they have been implemented
rapidly, despite clinicians/patients having limited remote
consultation experience [2]. Consequently, clinicians
may feel reluctant to make diagnoses/escalate immuno-
suppression without seeing patients in person, leading
to many remote consultations converting to face-to-face
reviews. This is particularly true for newly referred
patients, with many rheumatology clinicians avoiding the
use of remote appointments for new patients [3].
To date, research on the effectiveness of remote rheu-
matology consultations is limited mainly to established
conditions, with trained presenters examining patients
[4]. Only one UK-based study has described unselected
remote consultation outcomes in the COVID-19 pan-
demic [5]; it did not report new and follow-up consulta-
tions separately.
Understanding in whom remote consultations are
most effective is an issue of crucial importance; if many
newly referred patients require face-to-face reviews, an
argument could be made for offering them these initially.
To address this knowledge gap, we conducted an eval-
uation of our remote service at the Haywood Hospital
(Stoke-on-Trent) to understand how often/why new-
patient and follow-up patient consultations converted to
face-to-face reviews. We also evaluated how often
newly referred patients received a diagnosis/treatment
change/were discharged and how often patients with
established inflammatory arthritis/vasculitis/CTD diagno-
ses received alterations in immunosuppression.
We evaluated all newly referred patients and follow-up
patients with diagnoses of inflammatory arthritis/CTD/
vasculitis, aged 18 years and receiving remote consul-
tations during April–June 2020 (new referrals: all weeks;
follow-up patients: second weeks). Data were extracted
retrospectively from clinic letters. For all consultations,
we recorded whether they converted to a face-to-face
consultation for their next review and the reason/time
frame for this. For new referrals, we recorded the indica-
tion, diagnosis made, whether treatment was initiated
and whether patients were discharged. For follow-up
consultations, we recorded the diagnosis, whether their
disease was considered active (based on the clinician’s
opinion in the letter); if active, whether they were offered
an increase in DMARD/CS treatment and whether they
accepted this; and if inactive, whether they were offered
a decrease in DMARD treatment and whether they
accepted this. Data were analysed descriptively using
R (v.4.0.3) and summarized as means/proportions. The
evaluation was registered with our trust’s service evalua-
tion department. Ethical approval was not required.
Three hundred and thirteen new-patient consultations
occurred (303 telephone; 10 telephone and video). The
mean patient age was 53.7 (95% CI: 51.7, 55.6) years;
207 (66.1%) were female, and 274 (87.5%) of White
British ethnicity. Commonest referral reasons comprised
arthralgia [93 (29.7%) patients], suspected synovitis [90
(28.8%) patients] and suspected CTD [52 (16.6%)
patients]. Definite and probable/possible diagnoses
were made in 38 (12.1%) and 227 (72.5%) patients, re-
spectively. Of these, the commonest diagnoses were
OA, RA, FM, CTD and peripheral SpA [41 (15.5%), 36
(13.6%), 32 (12.1%), 30 (11.3%) and 26 (9.8%) patients,
respectively]. In 48 (15.3%) patients, no diagnosis was
made. Fifty-five (17.6%) patients were discharged, in
whom the commonest diagnoses comprised OA, FM
and a positive ANA without associated features of a
rheumatological condition [14 (25.5%), 10 (18.2%) and 9
(16.4%) patients, respectively]. Ninety-six (30.7%)
patients received drug treatment (19 a DMARD; 25 a
CS; 51 an analgesic).
Two hundred and ninety-six follow-up appointments
occurred (293 telephone; 3 telephone and video), with
two patients seen twice over the time period. The
mean patient age was 63.2 (95% CI: 61.5, 64.9) years;
188 (63.9%) were female, and 284 (96.6%) of White
British ethnicity. The commonest condition was RA
[175 (59.5%) patients], followed by undifferentiated in-
flammatory arthritis [41 (13.9%) patients], CTD [31
(10.5%) patients], vasculitis [24 (8.2%) patients], pe-
ripheral SpA [15 (5.1%) patients] and axial spondyloar-
thritis [8 (2.7%) patients]. In 146 (49.3%) and 138
(46.6%) consultations, patients were felt to have ac-
tive and inactive disease, respectively (disease activity
unclear in 12). In those with active disease, 67 (45.9%)
were offered an escalation in DMARDs/CSs, 54 of
whom accepted this (Fig. 1). In those with inactive dis-
ease, 14 (10.1%) were offered a reduction in
DMARDs, 13 of whom accepted this.
Nearly two-thirds [196 (62.6%)] of new-patient
appointments converted to face-to-face consultations
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FIG. 1 Bar charts of treatment decisions and face-to-face consultation conversions in patients receiving remote
consultations
For all bar charts, the percentage of patients is provided at the top of the bar. (A) People with inflammatory arthritis/
CTD/vasculitis felt to have active disease and offered an increase in immunosuppression. (B) People with inflamma-
tory arthritis/CTD/vasculitis felt to have active disease and offered an increase in immunosuppression who accepted
this increase. (C) People with inflammatory arthritis/CTD/vasculitis felt to have inactive disease and offered a de-
crease in immunosuppression. (D) People with inflammatory arthritis/CTD/vasculitis felt to have inactive disease and
offered a decrease in immunosuppression who accepted this decrease. (E) People receiving a new-patient remote
consultation converting to a face-to-face review. (F) People receiving a follow-up remote consultation converting to a
face-to-face review.
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for their next review (Fig. 1); the reason in 192 of these
was to perform an examination. Most [113 (57.7%)]
were scheduled to occur as soon as possible/within
1 month. Nearly one-quarter [85 (28.7%)] of follow-up
appointments converted to a face-to-face consultation,
of which 69 were to perform an examination to establish
disease activity. Twenty-eight (32.9%) were scheduled
to occur as soon as possible/within 1 month.
Our evaluation, the chief limitation of which is that it
evaluated data from a single centre, limiting generaliz-
ability, has three findings. First, given that nearly
two-thirds of new-patient consultations converted to
face-to-face reviews to conduct examinations, remote
approaches seem better placed to deliver care to people
with established diagnoses. Second, although clinicians
feel able to assess disease activity remotely, they appear
reluctant to alter immunosuppression in the pandemic
setting, despite many patients being agreeable to
alterations in immunosuppression. Third, a substantial
proportion (28.3%) of patients with inflammatory arthritis/
vasculitis/CTD continue to require face-to-face examina-
tions to confirm disease activity. Many patient-reported
outcome measures have been validated to assess
disease activity in people with inflammatory arthritis
[6, 7]. We consider that the feasibility and merits of using
these to inform decision-making and deliver treat-to-
target strategies [8] remotely requires urgent evaluation.
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